Patents by Inventor Sven Taylor

Sven Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles
    Patent number: 7253281
    Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: August 7, 2007
    Assignees: Hoffmann-La Roche Inc., Vernalis Research Limited
    Inventors: Jonathan Mark Bentley, Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Cyclohexyl piperazinyl methanone derivatives
    Publication number: 20070167436
    Abstract: The present invention relates to compounds of formula I wherein s, R1a and R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
    Type: Application
    Filed: January 4, 2007
    Publication date: July 19, 2007
    Inventors: Matthias Nettekoven, Jean-Marc Plancher, Olivier Roche, Tadakatsu Takahashi, Sven Taylor
  • Tricyclic amide derivatives
    Publication number: 20070135416
    Abstract: The present invention relates to compounds of formula I wherein A, G, r and R1 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
    Type: Application
    Filed: November 29, 2006
    Publication date: June 14, 2007
    Inventors: Matthias Nettekoven, Jean-Marc Plancher, Hans Richter, Olivier Roche, Sven Taylor
  • 1,5-Substituted indol-2-yl amide derivatives
    Publication number: 20070123515
    Abstract: The present invention relates to compounds of formula I wherein R1 to R4 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
    Type: Application
    Filed: November 27, 2006
    Publication date: May 31, 2007
    Inventors: Matthias Nettekoven, Jean-Marc Plancher, Hans Richter, Oliver Roche, Valerie Runtz-Schmitt, Sven Taylor
  • 5-Substituted indole-2-carboxamide derivatives
    Publication number: 20070123525
    Abstract: The present invention relates to compounds of formula I wherein R1 to R4 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
    Type: Application
    Filed: November 27, 2006
    Publication date: May 31, 2007
    Inventors: Matthias Nettekoven, Jean-Marc Plancher, Hans Richter, Olivier Roche, Sven Taylor
  • 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives
    Publication number: 20070123526
    Abstract: The present invention relates to compounds of formula I wherein R1, R2 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
    Type: Application
    Filed: November 28, 2006
    Publication date: May 31, 2007
    Inventors: Matthias Nettekoven, Jean-Marc Plancher, Hans Richter, Olivier Roche, Rosa Rodriguez Sarmiento, Sven Taylor
  • Heterocyclic CB1 receptor antagonists
    Patent number: 7220743
    Abstract: The present invention relates to compounds of formula wherein R1 and R2 are each independently hydrogen or halogen. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: May 22, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Marc Plancher, Sven Taylor
  • Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles
    Publication number: 20070106076
    Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a] indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
    Type: Application
    Filed: January 3, 2007
    Publication date: May 10, 2007
    Inventors: Jonathan Bentley, Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Spiro-pentacyclic compounds
    Patent number: 7144890
    Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors including obesity.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: December 5, 2006
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jean-Marc Plancher, Sven Taylor
  • 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives
    Patent number: 7098337
    Abstract: The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts, solvates and esters thereof. These compounds can be used to prepare pharmaceutical compositions for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: August 29, 2006
    Assignees: Hoffmann-La Roche Inc., Vernalis Research Limited
    Inventors: David Reginald Adams, Jonathan Mark Bentley, Toby Jonathan Blench, Paul Hebeisen, Nathaniel Julius Thomas Monck, Hans Richter, Stephan Roever, Jonathan Richard Anthony Roffey, Sven Taylor
  • Heterocyclic CB1 receptor antagonists
    Publication number: 20060100206
    Abstract: The present invention relates to compounds of formula wherein R1 and R2 are each independently hydrogen or halogen. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Application
    Filed: November 3, 2005
    Publication date: May 11, 2006
    Inventors: Jean-Marc Plancher, Sven Taylor
  • Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles
    Publication number: 20050239789
    Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
    Type: Application
    Filed: June 28, 2005
    Publication date: October 27, 2005
    Inventors: Jonathan Bentley, Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Spiro-pentacyclic compounds
    Publication number: 20050165012
    Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors including obesity.
    Type: Application
    Filed: January 25, 2005
    Publication date: July 28, 2005
    Inventors: Jean-Marc Plancher, Sven Taylor
  • Thiazole derivatives
    Publication number: 20050038073
    Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents have the significance given in the specification, and the compounds are neuropeptide Y(NPY) antagonists which are useful in the treatment of obesity.
    Type: Application
    Filed: August 10, 2004
    Publication date: February 17, 2005
    Inventors: Werner Neidhart, Matthias Nettekoven, Philippe Pflieger, Sven Taylor
  • Piperazine derivatives
    Patent number: 6844345
    Abstract: The present invention provides piperazine derivatives in accordance with formula (I) as well as salts, hydrates and esters thereof. The substituent designations are as provided in the specification. The compounds of the present invention can be used in the treatment of type II diabetes or obesity.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: January 18, 2005
    Assignees: Hoffman-La Roche Inc., Vernal Research Limited
    Inventors: Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Thiazole derivatives
    Patent number: 6686381
    Abstract: Compounds of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5, n, m and A have the significance disclosed in the specification, and can be used for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: February 3, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Patrizio Mattei, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger, Sven Taylor
  • THIAZOLE DERIVATIVES
    Publication number: 20030225141
    Abstract: Compounds of formula I are provided 1
    Type: Application
    Filed: February 26, 2003
    Publication date: December 4, 2003
    Inventors: Patrizio Mattei, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger, Sven Taylor
  • Piperazine derivatives
    Publication number: 20030207888
    Abstract: The present invention relates to compounds of formula (I) 1
    Type: Application
    Filed: January 24, 2003
    Publication date: November 6, 2003
    Inventors: David Reginald Adams, Jonathan Mark Bentley, Toby Jonathan Blench, Paul Hebeisen, Nathaniel Julius Thomas Monck, Hans Richter, Stephan Roever, Jonathan Richard Anthony Roffey, Sven Taylor
  • Fused indole derivatives
    Patent number: 6610685
    Abstract: The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salt, solvate and ester thereof, wherein R1 to R4 and n are as defined in the specification. A compound of formula 1 is useful as a pharmaceutical composition for the treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: August 26, 2003
    Assignees: Hoffmann-La Roche Inc., Vernalis Research Limited
    Inventors: Jonathan Mark Bentley, Michael John Bickerdike, Paul Hebeisen, Guy Anthony Kennett, Sean Lightowler, Patrizio Mattei, Jacques Mizrahi, Timothy James Morley, Jean-Marc Plancher, Hans Richter, Stephan Roever, Sven Taylor, Steven Paul Vickers
  • Aza- indolyl derivatives for treating obesity
    Patent number: 6583134
    Abstract: Novel compounds of formula (I): wherein X1, X2, X3 and X4, n, R1, R2 and R3 are defined in the specification, and pharmaceutically acceptable salts and prodrugs of the compounds of formula (I) have therapeutic uses. These compounds are useful for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. They are particularly useful for the treatment of obesity.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: June 24, 2003
    Assignees: Hoffman-La Roche Inc., Vernalis Research Limited
    Inventors: Jonathan Mark Bentley, Paul Hebeisen, Sven Taylor